Related Experiment Videos
Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole
1Diabetes and Metabolism Research Unit, Section of Endocrinology, Evans Department of Medicine and the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
The Journal of Biological Chemistry
|July 8, 2000
Summary
The Raf/MEK/MAPK pathway is essential for cell cycle progression into mitosis. Nocodazole treatment reveals this pathway
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- Microtubule dynamics are crucial for cell division (mitosis).
- Drugs like nocodazole disrupt microtubules, arresting cells in mitosis.
- The Raf/MEK/MAPK pathway's role in mitosis is not fully understood.
Purpose of the Study:
- To investigate the activation and role of the Raf/MEK/MAPK pathway during nocodazole-induced mitosis.
- To determine how this pathway influences cell cycle progression at G2/M.
Main Methods:
- Utilized nocodazole to induce mitosis in cells.
- Employed MEK inhibitors (PD98059, U0126) to block MAPK activation.
- Assessed Raf-1 and MEK/MAPK activity and localization.
- Analyzed Raf-1 binding to 14-3-3 proteins.
Main Results:
- Raf/MEK/MAPK pathway activation occurs early in nocodazole treatment, promoting G2/M transition.
- Inhibition of MAPK signaling causes a G2 block.
- Mitotic MAPK activation is inhibited, despite sustained Raf-1 activity.
- Raf-1 binding to 14-3-3 proteins increases during mitosis and is vital for Raf-1 activity.
Conclusions:
- Activation of the Raf/MEK/MAPK pathway is required for progression through G2 and into mitosis.
- 14-3-3 binding regulates Raf-1 activity during mitosis.